[PDF][PDF] Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

…, CH Mitton, RO Payne, M Marks, H Maxwell-Scott… - Med, 2021 - cell.com
Background Development of an effective vaccine against the pathogenic blood-stage infection
of human malaria has proved challenging, and no candidate vaccine has affected blood-…

[HTML][HTML] Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly

…, M Zaric, M Mulatier, RL Ramon, M Baker, CH Mitton… - JCI insight, 2021 - ncbi.nlm.nih.gov
Controlled human malaria infection (CHMI) provides a highly informative means to investigate
host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of new …

[HTML][HTML] Safety and immunogenicity of a novel recombinant simian adenovirus ChAdOx2 as a vectored vaccine

…, NJ Edwards, CF Mair, G Bowyer, I Poulton, CH Mitton… - Vaccines, 2019 - mdpi.com
Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune
responses which are particularly effective against intracellular pathogens. Recombinant simian …

[HTML][HTML] Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics

…, Y Themistocleous, JR Barrett, CH Mitton… - Frontiers in …, 2022 - frontiersin.org
In endemic settings it is known that natural malaria immunity is gradually acquired following
repeated exposures. Here we sought to assess whether similar acquisition of blood-stage …

Controlled human malaria infection with PvW1 – a new clone of Plasmodium vivax with high quality genome assembly

…, M Zaric, M Mulatier, RL Ramon, M Baker, CH Mitton… - medRxiv, 2021 - medrxiv.org
Controlled human malaria infection (CHMI) provides a highly informative means to investigate
host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of new …

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5. 1/AS01B in a phase I/IIA clinical trial

AM Minassian, SE Silk, ID Poulton, CH Mitton… - AMERICAN JOURNAL …, 2017 - ora.ox.ac.uk
594 astmh.org Page 1 594 astmh.org at the household level with an agent-based mathematical
model and investigated the effects of various case management rates, maintenance of …

Efficacy of the novel Plasmodium falciparum blood-stage vaccine RH5. 1/AS01B in a phase I/IIA clinical trial

A Minassian, S Silk, I Poulton, C Mitton… - American Journal of …, 2018 - ora.ox.ac.uk
Recent efforts in malaria control in Tanzania mainland has led to progressive changes in the
epidemiological profile of malaria with prevalence in children aged 6-59 months declining …

Mountain pine beetle develops an unprecedented summer generation in response to climate warming

JB Mitton, SM Ferrenberg - The American Naturalist, 2012 - journals.uchicago.edu
The mountain pine beetle (MPB; Dendroctonus ponderosae) is native to western North America,
attacks most trees of the genus Pinus, and periodically erupts in epidemics. The current …

[HTML][HTML] Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

…, J Hollidge, I Poulton, M Baker, C Mitton… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Prostate cancer (PCa) has been under investigation as a target for antigen-specific
immunotherapies in metastatic disease settings for the last two decades leading to a …

[HTML][HTML] Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

D Jenkin, D Wright, PM Folegatti, A Platt… - The Lancet Infectious …, 2023 - thelancet.com
Background Rift Valley fever is a viral epidemic illness prevalent in Africa that can be fatal or
result in debilitating sequelae in humans. No vaccines are available for human use. We …